MERIDIAN RESEARCH

🧭 MACRO SNAPSHOT

The April payrolls print of +115K (CNBC) came in above expectations but continues a clear cooling trajectory; unemployment held at 4.3% (FRED). With Fed Funds at 3.64%, the 2s/10s curve at +49bp (3.92% / 4.41%, FRED), and HY credit spreads at a remarkably tight 279bp (FRED), the bond market is pricing a soft landing — not a recession. GDP growth at 2.0% with real GDP at $24.17T confirms a still-expanding but decelerating economy. The CPI print at 330.3 (index level) suggests inflation remains the binding constraint on further Fed cuts; the bar for accelerated easing is high without a real labor break.

For the portfolio: tight HY spreads + a positive curve = risk-on regime, which favors our quality compounders (MSFT, GOOGL, NVDA) and rate-sensitive growth (ESTC, ZS, HUBS). The Iran ceasefire holding (per IBD) removes a material oil-shock tail risk — bearish for XOM's near-term thesis, neutral-to-positive for everything else. S&P at 7,398.93 means we are paying full price for quality; selectivity matters more than ever.

₿ BITCOIN UPDATE

Action: STRONG HOLD | Conviction: 9/10 | Price: $80,393 (+2.9% 7d, +13.0% 30d)

No structural change this week. We remain ~13 months post-halving — historically the most kinetic phase of the 4-year cycle — and dominance at 58.2% suggests capital has not yet rotated aggressively into alts, which typically marks late-cycle behavior. The 30-day +13% move with no narrative catalyst is consistent with steady spot ETF accumulation and supply tightening. Thesis reaffirmed: we are mid-cycle in the post-halving liquidity window, and the structural setup (institutional flows, tightening supply, macro liquidity) remains intact. No action required.

🔬 TODAY'S DEEP DIVES

ESTC — Elastic N.V. — NEW IDEA

Conviction: 6/10 | Status: MONITORING | Sector: Software / Data Infrastructure

WHAT THEY DO: Elastic is the commercial company behind the Elastic Stack ("ELK" — Elasticsearch, Logstash, Kibana), an open-source-rooted search and analytics platform. They make money by selling managed cloud subscriptions and self-managed enterprise licenses across three solution areas: Enterprise Search, Observability (logs/metrics/APM, competing with Datadog and Splunk), and Security (SIEM, competing with Splunk and CrowdStrike).

WHY IT'S INTERESTING NOW: Elastic has rebranded as a "Search AI" platform, and the rise of retrieval-augmented generation (RAG) — where LLMs query vector databases to ground their answers — sits directly in Elastic's wheelhouse. The market is pricing ESTC like a stagnant logs vendor (3.2x P/S) when the actual workload mix is shifting toward AI-adjacent search at exactly the moment FCF is inflecting (~23% FCF margin, $390M on $1.7B).

BULL CASE:

• AI/RAG tailwind is real and underpriced at 3.2x P/S, ~14x EV/FCF — a deep discount to data infrastructure peers (DDOG ~15x sales, MDB ~9x sales). If vector search adoption accelerates, ESTC monetizes its installed base without large CAC. (Source: yfinance multiples)
• FCF inflection is meaningful: $390M FCF on $1.7B revenue (~23% margin) demonstrates the cost discipline phase has been executed — operating leverage from here is incremental. (Source: ESTC 10-K)

BEAR CASE:

• Hyperscaler/OpenSearch competitive pressure: AWS OpenSearch (forked from Elasticsearch in 2021) is free, deeply integrated into AWS, and improving. This caps Elastic's pricing power on its core search workload — the very workload AI/RAG needs. (Source: AWS OpenSearch documentation)
• Datadog's Q1 blowout (DDOG +31% on earnings) signals competitors are capturing observability share faster than Elastic can convert AI tailwinds.

KEY METRICS: Revenue growth ~15-17% TTM, FCF margin ~23%, P/S 3.2x, EV/FCF ~14x. Differentiator: largest open-source search install base globally (~50K+ deployments).

BOTTOM LINE: Worth monitoring at 6/10 — valuation is attractive but the OpenSearch overhang is a real structural concern, not a sentiment issue.

PGNY — Progyny, Inc. — NEW IDEA + ROLLING REVIEW

Conviction: 6/10 | Status: MONITORING | Sector: Healthcare / Specialty Benefits

WHAT THEY DO: Progyny is a specialty benefits manager that contracts with self-insured Fortune 500 employers to administer fertility, family-building, and women's/maternal health benefits. Their differentiator is the "Smart Cycle" treatment bundle paired with a concierge Patient Care Advocate model — they get paid per member per month plus utilization-based fees, and have proven ROI data showing better clinical outcomes (higher live-birth rates per cycle, lower multiple-birth complications) than traditional carriers.

WHY IT'S INTERESTING NOW: The stock is up 45.5% in the past month and 25.4% in the past week following Q1 2026 earnings (8-K filed 2026-05-07). The question on rolling review: is this rerating fundamentally justified, or is the margin of safety now compromised? Forward P/E has compressed to 11.1x against a TTM of 30.8x, signaling the Street expects an earnings inflection that the company has now begun to deliver.

BULL CASE:

• Secular tailwind in fertility benefits adoption: Per Mercer/SHRM employer surveys, large-employer fertility coverage has grown from ~25% in 2020 to ~45%+ in 2024 (industry reports, not yet primary-verified). PGNY is the dominant pure-play.
• Forward P/E of 11.1x vs. TTM 30.8x signals expected earnings inflection — Q1 results appear to validate the thesis.
• Margin expansion runway: as utilization stabilizes post-COVID and contract pricing strengthens, gross margins should structurally improve.

BEAR CASE:

• Revenue growth has decelerated sharply to 6.7% TTM, well below the 50%+ historical norms. This is the single most important data point — if TAM is more saturated among target employers than bulls assume, the multiple compresses again.
• Customer concentration: Amazon was reportedly moving volume in-house. Loss of any top-5 client would meaningfully reset growth.
• Post-rally entry point now offers materially less margin of safety than the initial coverage at -45% lower.

KEY METRICS: Revenue growth 6.7% TTM, Forward P/E 11.1x, TTM P/E 30.8x. Differentiator: only at-scale specialty fertility benefits manager with contracted ROI data.

BOTTOM LINE: Conviction held at 6/10 — the business is real and the secular tailwind is real, but the rally has eaten the margin of safety; I want either a pullback or two more clean quarters of accelerating growth before raising conviction.

📋 TARGET LIST STATUS

Changes: Two names dropped today — HOOD and NTRA, both at 6/10 conviction. Both displaced by ESTC and PGNY, also at 6/10, but with cleaner near-term catalysts (ESTC's AI/RAG repricing setup at 3.2x sales; PGNY's Q1 earnings inflection). Honest disclosure: these are lateral conviction swaps, not upgrades — when the bench is full of 6/10s, recency of catalyst becomes the tiebreaker. ANET dropped 17.9% on the week post-Q1; thesis intact, monitoring whether the softer 2026 outlook is a one-quarter reset or a deeper hyperscaler capex digestion.

💼 YOUR PORTFOLIO

• AAPL | 200 sh @ $50.46 | HOLD | 8/10 — Foundational holding, +455% unrealized. Services + installed-base monetization remain durable; not adding at $280, not selling.
• ALTO | 3,000 sh @ $1.04 | TRIM | 4/10 — +422% on a small-cap specialty ethanol name. The structural thesis hasn't strengthened with the rerating; trim at least 30% to lock gains.
• BABA | 40 sh @ $127.86 | HOLD | 7/10 — China e-commerce/cloud at deep structural discount; thesis intact at +2.8% P&L.
• FSLR | 10 sh @ $186.18 | HOLD | 7/10 — Best-in-class U.S. CdTe manufacturer with policy moat; +13.7% and adding only on weakness.
• GOOGL | 32 sh @ $320.20 | STRONG HOLD | 9/10 — Highest-conviction equity holding; Search + Cloud + YouTube + Waymo optionality at reasonable multiple. +20.5%.
• HIMS | 200 sh @ $45.12 | TRIM | 5/10 — Down 39%; original DTC pharmacy thesis impaired by GLP-1 compounding regulatory overhang. Trim into any rally.
• ISRG | 5 sh @ $578.24 | HOLD | 8/10 — Down 20.8% but da Vinci moat (~80% share) is structural; this is a duration name not a momentum trade.
• MKL | 13 sh @ $909.50 | HOLD | 7/10 — Mini-Berkshire, +95.6%. Specialty insurance + Markel Ventures continues compounding.
• PLTR | 12 sh @ $176.97 | HOLD | 6/10 — Down 18.6%; commercial AIP traction remains the thesis, but valuation still rich. Hold, don't add.
• SEG | 210 sh @ $22.91 | HOLD | 5/10 — Spinoff entertainment owner-operator; small position, story still TBD.
• SOUN | 270 sh @ $11.13 | HOLD | 6/10 — Down 14.1%; small-cap voice AI bet, position size already appropriate to risk.
• TSLA | 83 sh @ $419.09 | TRIM | 5/10 — Down 6.7%; auto economics deteriorating, robotaxi/Optimus optionality not yet de-risked at this multiple.
• U | 100 sh @ $25.98 | HOLD | 6/10 — Real-time 3D platform, +4.4%; turnaround story, monitor mobile ad recovery.
• UNH | 15 sh @ $314.29 | HOLD | 7/10 — Integrated managed care leader, +17.3%; medical loss ratio normalization is the key 2026 story.

⚠️ WATCH LIST

• ANET (-17.9% 1W): Fundamentals didn't break — Q1 beat, just softer 2026 guide. If hyperscaler capex commentary from MSFT/META/GOOG/AMZN remains constructive in next earnings cycle, this is an upgrade candidate to 8/10. Trigger: confirmation of FY26 cloud capex >$300B aggregate.
• HUBS (-20.2% 1W): Sharp drawdown demands diagnosis. If the move is sentiment-driven (software de-rating) rather than fundamental (NRR deterioration), conviction could move to 7/10. Trigger: review next earnings for net retention and SMB pipeline health.
• PGNY (+45.5% 1M): Conviction held at 6/10 today, but if the Q1 growth reacceleration sustains into Q2 and Mercer 2026 employer survey shows continued benefit adoption, this moves to 7/10. Trigger: Q2 revenue growth >12% YoY.
• XOM (-5.9% 1W): Iran ceasefire removed the upside oil-shock catalyst. If Brent settles below $70 sustainably, conviction drops to 5/10 and we evaluate displacement. Trigger: 30-day average Brent <$70.